GlassScriptPhysician profile
George M Sandoz
NPI 1013975010
$11,858.74
in general payments reported to CMS, 2019-2025
60 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,169 · 2020: $1,366 · 2021: $1,188 · 2022: $1,765 · 2023: $2,411 · 2024: $2,692 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,599 · Travel and Lodging: $572 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,599.17 |
| Travel and Lodging | $571.59 |
| Education | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,540.70 | 2019-2024 | Kesimpta |
| Acadia Pharmaceuticals INC | $830.09 | 2019-2025 | Nuplazid |
| Emd Serono, INC. | $765.85 | 2019-2023 | Mavenclad |
| Celgene Corporation | $577.51 | 2020-2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $523.68 | 2019-2024 | Austedo Xr |
| Ucb, INC. | $508.18 | 2019-2024 | Briviact, Rystiggo |
| Neurocrine Biosciences, INC. | $501.73 | 2019-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $453.24 | 2019-2025 | |
| Sk Life Science, INC. | $445.97 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $386.62 | 2019-2024 | Ultomiris |
| Abbvie INC. | $372.78 | 2021-2024 | Ubrelvy |
| Allergan, INC. | $344.57 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $337.10 | 2019-2020 | |
| Pfizer INC. | $313.69 | 2019-2024 | |
| Lundbeck LLC | $253.03 | 2023-2024 | Vyepti, Rexulti |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Sandoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.